^
    Back
    Association details:
    Biomarker:INPP4B mutations
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract 4287: INPP4B mutation as a novel biomarker for immunotherapy in patients with non-small cell lung cancer

    Published date:
    08/01/2020
    Excerpt:
    Survival analysis from the MSKCC cohort confirmed that patients with INPP4B GAs had a remarkable clinical benefit to ICIs compared to WT patients in both progression free survival (PFS) (13.17 months vs 3.23 months, respectively, p=0.041) and durable clinical benefit (DCB)~
    DOI:
    10.1158/1538-7445.AM2020-4287